These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The normal mouse in experimental chemotherapy. Levy L Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4 Suppl):843-6. PubMed ID: 3325577 [No Abstract] [Full Text] [Related]
24. Chemotherapy of the mycobacterial diseases--leprosy and tuberculosis. Krenzien HN Indian J Chest Dis Allied Sci; 1982; 24(2-3):223-32. PubMed ID: 6762341 [No Abstract] [Full Text] [Related]
25. A 6 week quadruple drug regimen for the treatment of multibacillary leprosy. Pattyn S; Grillone S Lepr Rev; 2000 Mar; 71(1):43-6. PubMed ID: 10820986 [No Abstract] [Full Text] [Related]
26. Prospects for chemotherapy of leprosy. Ji B Indian J Lepr; 2000; 72(2):187-98. PubMed ID: 11008659 [No Abstract] [Full Text] [Related]
27. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Jamet P; Ji B Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):622. PubMed ID: 7868967 [No Abstract] [Full Text] [Related]
32. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues. Dhople AM; Namba K Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987 [TBL] [Abstract][Full Text] [Related]
33. Is there a microbiological rationale for single-dose treatment of leprosy? Katoch VM Lepr Rev; 1998 Mar; 69(1):2-5. PubMed ID: 9628091 [No Abstract] [Full Text] [Related]
34. Progress in the chemotherapy of leprosy. Grosset JH Int J Lepr Other Mycobact Dis; 1994 Jun; 62(2):268-77. PubMed ID: 8046266 [No Abstract] [Full Text] [Related]
35. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi. Pönnighaus JM; Boerrigter G Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703 [TBL] [Abstract][Full Text] [Related]
36. A high incidence of viable Mycobacterium leprae in post-MDT recurrent lesions in tuberculoid leprosy patients. Shetty VP; Wakade A; Antia NH Lepr Rev; 2001 Sep; 72(3):337-44. PubMed ID: 11715280 [No Abstract] [Full Text] [Related]
37. Viability and drug sensitivity of M. leprae isolated from long-term WHO/MDT treated multibacillary leprosy patients. Habtemariam H Lepr Rev; 1999 Mar; 70(1):43-6. PubMed ID: 10405543 [No Abstract] [Full Text] [Related]
38. Effect of mono treatment and combined treatment on the morphology of Myco. lepare in the skin. Leiker DL Lepr Rev; 1975 Jun; 46(2 Suppl):73-9. PubMed ID: 1100967 [No Abstract] [Full Text] [Related]
39. [New WHO recommendations for the treatment of leprosy]. Acta Leprol; 1997; 10(4):189. PubMed ID: 9527754 [No Abstract] [Full Text] [Related]
40. Supervised administration of multidrug therapy in leprosy colonies through volunteers--a bacteriological assessment. Ganapati R; Naik SS; Revankar CR; Vartak RB; Desai AP; Panvalkar NA; Deshpande SS Indian J Lepr; 1986; 58(1):86-90. PubMed ID: 3528338 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]